

Curriculum Vitae

Hyo Song Kim

A. Date Curriculum Vitae is Prepared: 2017 March

Only includes Activities from March 1996 to March 2017

B. Biographical Information

Primary Office Severance Hospital, Yonsei University Health System
Yonsei Cancer Center
50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Korea
Telephone 82-2-2228-8124
Cellphone 82-10-6638-4338
Fax 82-2-393-3652
Email hyosong77@yuhs.ac, bbosong77@gmail.com

1. EDUCATION

Degrees

2008 Mar - 2013 Feb PhD, School of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic Of, Supervisor(s): Won Ki Kang, MD, PhD
2006 Mar - 2008 Feb MMS, School of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic Of, Supervisor(s): Won Ki Kang, MD, PhD
1996 Mar - 2002 Feb MD, School of Medicine Gyeongsang National University, Jinju, Korea

Postgraduate, Research and Specialty Training

2008 Mar - 2009 Feb Clinical fellowship, Hematology/Oncology, Division of Hematology/Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Republic Of, Supervisor(s): Won Ki Kang, MD, PhD
2007 June - 2007 July Visiting Residency, Division of Medical Oncology, National Cancer Center, Singapore, Supervisor(s): Soon Thye Lim, MD, PhD
2004 Mar - 2008 Feb Residency, Internal Medicine, Hematology/Oncology Subspecialty, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic Of
2003 Mar - 2003 Dec ESL course, English Language School in Vancouver, Canada
2002 Mar - 2003 Feb Internship program, Medicine (rotational), Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Republic Of

Qualifications, Certifications and Licenses

2009 Oct - present Specialist, Hematology/Oncology, Korean Association of Internal Medicine, Korea, Republic Of, License / Membership #: 6-10-369
2008 Mar - present Board license of Internal Medicine, Internal Medicine, Ministry of Health and Welfare, Seoul,

HYO SONG KIM

2002 Mar - present Korea, Republic Of, License / Membership #: 10924
Medical doctor license, Ministry of Health and Welfare, Korea, Republic Of,
License / Membership #: 76472

2009 Sep PNET (Primitive Neuroectodermal Tumor) Pacific Asian Summer School Certificate,
European Accreditation Council for Counting Medical Education, Berlin, Germany

2009 Sep Clinical Trial Training and Education Advanced Program for Investigators, Yonsei University
College of Medicine, Seoul, Korea

2015. Sep Certified for GCP training, Clinical Trial Center, Yonsei University College of Medicine, Seoul,
Korea, Republic Of

2017. March Completed GCP training, Korea Centers for disease control and prevention

Languages TOEIC: 895 in 2003, TOEFL: 85 (iBT) in 2006
April 2003 ~ September 2003 ELS (English Language School) in Vancouver, Canada

2. EMPLOYMENT

UNIVERSITY

2009 Mar – 2010 Feb Clinical Research Associate Professor, Department of Internal Medicine, Yonsei Cancer
Center, Yonsei University College of Medicine, Seoul, Korea, Republic Of

2010 Mar – 2017 Feb Clinical Assistant Professor, Department of Internal Medicine, Yonsei Cancer Center, Yonsei
University College of Medicine, Seoul, Korea, Republic Of

2017 Mar – present Assistant Professor, Department of Internal Medicine, Yonsei Cancer Center, Yonsei
University College of Medicine, Seoul, Korea, Republic Of

3. HONOURS AND CAREER AWARDS

Distinctions and Research Awards

2007 Dec **Outstanding Paper Award,**
Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University
School of Medicine, Seoul, Korea Republic Of
Clinical outcome of gastric cancer patients with bone marrow metastases, Oncology. 2007

2008 Dec **Young Investigator Travel Award**
Korean Association of Medical Science, Seoul, Korea, Republic Of.
Total Amount: 1,700 USD

2009 June **GlaxoSmithKline Outstanding Presentation Award**
Korean Cancer Society, Seoul, Korea, Republic Of.
Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with
different toxicity profiles, Oncology. 2011

2009 Dec **Young Investigator Award**
Asia Pacific Cancer Conference, Tsukuba, Japan. (travel award) *Total Amount: 1,000 USD*

2010 June **LG Medical Science Award**
Korean Association of Medical Science, Seoul, Korea, Republic Of.
*It is the most honorable medical award for young investigators in South Korea. Four most
distinguishable young investigators are usually awarded from clinical and basic fields of
medical society in Korea. Total Amount: 2,500 USD*

2011 June **Young Investigator Award**
9th International Gastric Cancer Conference, Seoul, Korea, Republic Of
Total Amount: 1,000 USD

HYO SONG KIM

2012 June **Roche Outstanding Paper Award**
Korean Cancer Society, Seoul, Korea, Republic Of. *Total Amount: 1,000 USD*

2014 June **Outstanding Paper Award**
Korean Cancer Society, Seoul, Korea, Republic Of. *Total Amount: 1,000 USD*

4. PROFESSIONAL AFFILIATIONS AND ACTIVITIES

Professional Associations

2008 Jan - present **Active member**, Korean Cancer Study Group

2008 Jan - present **Active member**, Korean Association for Clinical Oncology

2008 Jan - present **Active member**, Korean Cancer Society

2009 May - present **International Member**, American Society of Clinical Oncology

2009 May - present **Associate Member**, American Association of Cancer Research

Administrative Activities

Other Organizations

2015 - present **Member**, Asian Sarcoma Advisory Board, Singapore

Korean Cancer Study Group

20013 Jan - Present **Secretary**, Committee of Rare Cancer, Seoul, Korea, Republic Of.

Yonsei University College of Medicine

2008 Feb - Present **Project Organizer**, Yonsei University College of Medicine, Seoul, Korea, Republic Of
This is a database project to install the electronic medical record database system for chemotherapy in Yonsei University College of Medicine. I am responsible for doctor's aspects of organization and utilization of electronic medical record database system, structuring database structures, applying it to clinical fields, and beta-testing it.

Peer Review Activities

MANUSCRIPT REVIEWS

Reviewer

2014 May - present Oncotarget, Number of Reviews: 5

2012 Apr - present Cancer Research and Treatment, Number of Reviews: 4

2012 Jul - present Yonsei Medical Journal, Number of Reviews: 2

2010 Feb - present Gastric Cancer, Number of Reviews : 2

C. Research Funding

1. GRANTS, CONTRACTS AND CLINICAL TRIALS

PEER-REVIEWED GRANTS

2015 Nov – Present **Principal Investigator.**

Tumor-microenvironment-related predictive biomarkers for neoadjuvant chemoradiotherapy in gastric cancer. Korean government, Ministry of Science, ICT and Future Planning. 130,000 USD [Grants]

- 2015 Oct – Present **Principal Investigator.**
Biomarker-driven umbrella trial in gastric cancer. (6-2015-0169). Yonsei University College of Medicine 20,000 USD [Grants]
- 2015 June – Present **Principal Investigator.**
Oncomine-Based Assignment of Cancer Therapy for Patients with Solid tumors. Yonsei University College of Medicine, Severance Biomedical Science Institute. [Research assay]
- 2015 Oct - 2016 Feb **Main Co-Investigator (hypothesis generation, writing whole research protocol, and clinical process manager).**
Umbrella Trial for Triple Negative Gastric Cancer, Korean government Ministry for Health, Welfare and Family Affairs. 440,000 USD [Grants]
This is the largest grant for cancer trial in Korea supported by Ministry of Health & Welfare. For this project, I mainly conducted every process from hypothesis generation to establish multicenter clinical trial.
- 2014 Dec – 2015 Nov **Co-Investigator.**
Personalized treatment based on gene alteration of circulating tumor cells in solid tumors. Korean government Ministry for Health, Welfare and Family Affairs. 155,000 USD [Grants]
- 2010 Sep - 2011 Mar **Co-Investigator.**
Development of DNA chip assay as predictive tool for solid tumors. Korean government Ministry for Health, Welfare and Family Affairs. 860,000 USD [Grants]
- 2009 June - 2010 Apr **Principal Investigator.**
Antitumor activity of Akt inhibitor in gastric cancer (2009-0443). Korean government Ministry for Health, Welfare and Family Affairs, 10,000 USD [Grants]
- 2009 Mar - 2011 Feb **Principal Investigator.**
PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer. (2009-310615). Yonsei University College of Medicine 10,000 USD [Grants]

NON-PEER-REVIEWED GRANTS

- 2017 Jan - present **Principle Investigator.**
A Multicenter Phase 2 Trial of pemetrexed/cisplatin for metastatic sarcoma
- 2014 Mar - present **Principle Investigator.**
A Multicenter Phase 2 Trial of Imatinib for Desmoid Tumors [NCT02495519, Clinical Trial]
- 2015 Jun - present **Principal Co-Investigator (hypothesis generation, writing whole research protocol, and clinical process manager).**

Phase II Clinical Trial with Afatinib and Paclitaxel Combination as 2nd Line Treatment for EGFR Positive Gastric Cancer, Boehringer Ingelheim, [NCT02501603, Clinical Trial]
For this project, I mainly conducted every process from hypothesis generation to establish multicenter clinical trial.

2015 June accepted

Principal Co-Investigator (hypothesis generation, writing whole research protocol, and clinical process manager).

A phase Ib/II study of first line pembrolizumab in combination with trastuzumab, capecitabine, and cisplatin in HER2 positive gastric cancer. [Clinical Trial]
For this project, I mainly conducted every process from hypothesis generation to establish multicenter clinical trial.

2014 Nov - present

Principal Co-Investigator (hypothesis generation, writing whole research protocol, and clinical process manager).

Phase II neo-adjuvant treatment with S-1, Cisplatin-based Chemoradiotherapy after Induction Chemotherapy for Locally Advanced Gastric Adenocarcinoma [NCT02495493, Clinical Trial]
For this project, I mainly conducted every process from hypothesis generation to establish multicenter clinical trial.

2012 Nov - present

Principal Co-Investigator (hypothesis generation, writing whole research protocol, and clinical process manager).

Phase II clinical trial with pazopanib for metastatic renal cell carcinoma with brain metastasis [Clinical Trial]

2010 Nov – 2014 Sep

Principal Site Investigator.

Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
[Clinical Trial, NCT01130025]

D. Publications

1. PEER-REVIEWED PUBLICATIONS

Journal Articles

1. **HS Kim**, SJ Shin, SH Beom, M Jung, YY Choi, T Son, HI Kim, JH Cheong, WJ Hyung, SH Noh, HChung, JC Park, SK Shin, SK Lee, YC Lee, WS Koom, JS Lim, HC Chung, SY Rha, H Kim. Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. *Oncotarget*, Vol 7, No. 28, 44608-44620 Impact Factor 6.359 **First Author**
2. **Kim HS**, Lee SE, Bae YS, Kim DJ, Lee CG, Hur J, Chung H, Park JC, Jung da H, Shin SK, Lee SK, Lee YC, Kim HR, Moon YW, Kim JH, Shim YM, Jewell SS, Kim H, Choi YL, Cho BC. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma. *Oncotarget*. 2015 Feb 10;6(4):2562-72. Impact Factor 6.359 **First Author**
3. **Kim HS**, Lee SE, Bae YS, Kim DJ, Lee CG, Hur J, Chung H, Park JC, Jung da H, Shin SK, Lee SK, Lee YC, Kim HR, Moon YW, Kim JH, Shim YM, Jewell SS, Kim H, Choi YL, Cho BC. PIK3CA Amplification Is Associated with Poor Prognosis among Patients with Curatively Resected Esophageal Squamous Cell Carcinoma. *Oncotarget*. 2015 Nov Impact Factor 6.359 **First Author**

HYO SONG KIM

4. Kim C, Cho YJ, Kim SH, Rha SY, Ahn JB, Yang WI, Lee YH, Suh JS, Roh JK, Kim KS, Choi YD, Shin KH, **Kim HS**. Different Subtypes of Epithelioid Sarcoma and Their Clinical Implication: Long-term Multi-institutional Experience with a Rare Sarcoma. 2015 Oncology Impact Factor 2.53. **Corresponding author**
5. Ji Soo Park, **Hyo Song Kim**, Sung Young Rha, Sung Hoon Noh, Hyunki Kim.
Frequency and prognostic significance of EGFR expression and amplification in localized advanced gastric cancer. APMIS. 2015 Nov; Impact Factor 2.04. **First Author**
6. Kim HJ, Cho YJ, Kim SH, Rha SY, Ahn JB, Yang WI, Lee YH, Suh JS, Roh JK, Kim KS, Choi YD, Shin KH, **Kim HS**. Leiomyosarcoma: investigation of prognostic factors for risk-stratification model. Int J Clin Oncol. 2015 Jun 28. Impact Factor 2.17 **Corresponding Author**
7. Yoo KH, **Kim HS**, Lee SJ, Park SH, Kim SJ, Kim SH, La Choi Y, Shin KH, Cho YJ, Lee J, Rha SY. Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series. BMC Cancer. 2015 Mar. Impact Factor 3.36, **First Author**
8. Park JS, Rha SY, Chung HC, Jung M, Kim KH, Jun HJ, Kim H, An JY, Kim HI, Cheong JH, Hyung WJ, Noh SH, **Kim HS**. Clinicopathological features and prognostic significance of HER2 expression in gastric cancer Oncology. 2015;88(3): Impact Factor 2.53 **Corresponding Author**
9. Zhang X, Park JS, Park KH, Kim KH, Jung M, Chung HC, Rha SY, **Kim HS**. PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer. Oncology. 2015;88(3). Impact Factor 2.53. **Corresponding Author**
10. Incidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and Children. Lim SM, Yoo CJ, Han JW, Cho YJ, Kim SH, Ahn JB, Rha SY, Shin SJ, Chung HC, Yang WI, Shin KH, Rho JK, **Kim HS**. Impact Factor 0.25. **Corresponding Author**
11. Park KS, **Kim HS**, Cho YJ, Rha SY, Ahn JB, Yang WI, Lee YH, Suh JS, Shin KH, Roh JK. Vascular soft-tissue sarcomas: a prognostic model from a retrospective single-center study. Oncology. 2014;86(5-6):329-35 Impact Factor 2.53. **First Author**
12. Lee YK, Jun HJ, Nahm JH, Lim TS, Park JS, Ahn JB, Rha SY, Chung HC, Oh HE, Song JS, Yang WI, **Kim HS**. Therapeutic strategies for well-differentiated papillary mesothelioma of the peritoneum. Jpn J Clin Oncol. 2013 Impact Factor 2.01. **Corresponding Author**
13. Lee JS, Lim SM, Rha SY, Roh JK, Cho YJ, Shin KH, Yang WI, Kim SH, **Kim HS** Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation study. J Clin Pathol. 2014 Impact Factor 2.92. **Corresponding Author**
1. **Kim HS**, Lee H, Jeung HC, Noh SH, Chung HC, Roh JK, Nam CM, Rha SY. Advanced detection of recent changing trends in gastric cancer survival: up-to-date comparison by period analysis. Jpn J Clin Oncol. Impact Factor 2.01. **First Author**
2. **Kim HS**, Hong MH, Kim K, Shin SJ, Ahn JB, Jeung HC, Chung HC, Koh Y, Lee SH, Bang YJ, Rha SY. Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. Oncology. 2011;80 Impact Factor 2.53. **First Author**
3. Kim JH, Rha SY, Kim C, Kim GM, Yoon SH, Kim KH, Kim MJ, Ahn JB, Chung HC, Roh JK, **Kim HS**. Clinicopathologic features of metachronous or synchronous gastric cancer patients with three or more primary sites. Cancer Res Treat. 2010 Dec Impact Factor 0.25. **Corresponding Author**
4. **Kim HS**, Kim EK, Jun HJ, Oh SY, Park KW, Lim do H, Lee SI, Kim JH, Kim KM, Lee DH, Lee J. Noncutaneous malignant melanoma: a prognostic model from a retrospective multicenter study. BMC Cancer. 2010

Apr Impact Factor 3.36. **First Author**

14. **Kim HS**, Yi SY, Jun HJ, Lee J, Park SH, Lee JK, Lee KT, Lee KH, Choi DW, Choi SH, Heo JS, Park YS, Lim HY, Kang WK, Park HC, Lim do H, Park JO
Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer. *Anticancer Drugs*. 2010
Impact Factor 1.784. **First Author**
15. **Kim HS**, Lee J, Yi SY, Jun HJ, Choi YL, Ahn GH, Seo SW, Lim do H, Ahn YC, Park JO, Kim SJ.
Liposarcoma: exploration of clinical prognostic factors for risk based stratification of therapy. *BMC Cancer*. 2009 Jun
26 Impact Factor 3.36. **First Author**
16. Kim Y, **Kim HS**, Cui ZY, Lee HS, Ahn JS, Park CK, Park K, Ahn MJ.
Clinicopathological implications of EpCAM expression in adenocarcinoma of the lung. *Anticancer Res*. 2009 May
Impact Factor 1.826. **First Author**
17. **Kim HS**, Kim KH, Kim KH, Chang MH, Ji SH, Lim do H, Kim K, Kim SJ, Ko Y, Ki CS, Jo SJ, Lee JW, Kim WS.
Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell
lymphoma. *Leuk Lymphoma*. 2009 May Impact Factor 2.891. **First Author**
18. **Kim HS**, Park YH, Park MJ, Chang MH, Jun HJ, Kim KH, Ahn JS, Kang WK, Park K, Im YH.
Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy
response in patients with metastatic breast cancer. *Breast Cancer Res Treat*. 2009 Nov; Impact 3.94. **First Author**
19. **Kim HS**, Park K, Jun HJ, Yi SY, Lee J, Ahn JS, Park YH, Kim S, Lee S, Ahn MJ.
Comparison of survival in advanced non-small cell lung cancer patients in the pre- and post-gefitinib eras. *Oncology*.
2009 Impact Factor 2.53. **First Author**
20. L1 cell adhesion molecule as a predictor for recurrence in pulmonary carcinoids and large-cell neuroendocrine tumors.
Kim HS, Yi SY, Jun HJ, Ahn JS, Ahn MJ, Lee J, Kim Y, Cui ZY, Hong HJ, Kim JM, Li S, Hwang IG, Park K. *APMIS*.
2009 Feb; Impact Factor 2.04. **First Author**
21. **Kim HS**, Kim WS, Park SH, Jung CW, Choi HY, Lee HM, Jeon SS, Ha H, Hwang IG, Lee S, Lim HY.
Molecular biomarkers for advanced renal cell carcinoma: implications for prognosis and therapy. *Urol Oncol*. 2010
Mar-Apr Impact Factor 2.76. **First Author**
22. **Kim HS**, Yi SY, Jun HJ, Lee J, Park JO, Park YS, Jang J, Kim HJ, Ko Y, Lim HY, Kang WK.
Clinical outcome of gastric cancer patients with bone marrow metastases. *Oncology*. 2007 Impact Factor 2.53. **First
Author**
23. Leem AY, Kim HS, Yoo BW, Kang BD, Kim MH, Rha SY, **Kim HS**. Ifosfamide-induced Fanconi syndrome with
diabetes insipidus. *Korean J Intern Med*. 2014 Mar Impact Factor 0.41 **Corresponding author**
24. **Kim HS**, Chang WI, Kim YC, Yi SY, Kil JS, Hahn JY, Kang M, Lee MS, Lee SH.
Catecholamine cardiomyopathy associated with paraganglioma rescued by percutaneous cardiopulmonary support:
inverted Takotsubo contractile pattern. *Circ J*. 2007 Dec **First Author**
25. Yi JH, Kang JH, Hwang IG, Ahn HK, Baek HJ, Lee SI, Lim DH, Won YW, Ji JH, **Kim HS**, Rha SY, Oh SY, Lee KE,
Lim T, Maeng CH, Kim MJ, Kim ST, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH.
A Retrospective Analysis for Patients with HER2 Positive Gastric Cancer who were Treated with Trastuzumab-based
Chemotherapy: In the Perspectives of Ethnicity and Histology. *Cancer Res Treat*. 2015 Aug 10, Impact Factor 0.25.
Coauthor or Collaborator.
26. Park JS, Lee JS, Kim EY, Jung JY, Kim SK, Chang J, Kim DJ, Lee CY, Jung I, Kim JH, Kim HR, Moon YW, **Kim HS**,
Cho BC, Shim HS.
The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer.
Lung Cancer. 2015 Jun, Impact Factor 3.73. **Coauthor or Collaborator**.

27. Lee CK, Jung M, Choi HJ, Kim HR, **Kim HS**, Roh MR, Ahn JB, Chung HC, Heo SJ, Rha SY, Shin SJ.
Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine. *Cancer Res Treat*. 2015 Aug 10, Impact Factor 0.25. **Coauthor or Collaborator**
28. Lee CK, Jung M, Jung I, Heo SJ, Jeong YH, An JY, Kim HI, Cheong JH, Hyung WJ, Noh SH, **Kim HS**, Rha SY, Chung HC.
Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy. *Ann Surg Oncol*. 2015 Oct Impact Factor 3.93. **Coauthor or Collaborator**
29. Park HS, Jung M, **Kim HS**, Kim HI, An JY, Cheong JH, Hyung WJ, Noh SH, Kim YI, Chung HC, Rha SY.
Proper timing of adjuvant chemotherapy affects survival in patients with stage 2 and 3 gastric cancer. *Ann Surg Oncol*. 2015 Jan Impact Factor 0.25 **Coauthor or Collaborator**
30. Kwon KA, Oh SY, Kim HY, **Kim HS**, Lee HY, Kim TM, Lim HY, Lee NR, Lee HJ, Hong SH, Rha SY.
Clinical features and treatment of collecting duct carcinoma of the kidney from the Korean cancer study group genitourinary and gynecology cancer committee. *Cancer Res Treat*. 2014 Apr Impact Factor 0.25 **Coauthor or Collaborator**
31. Kim HR, Park HS, Kwon WS, Lee JH, Tanigawara Y, Lim SM, **Kim HS**, Shin SJ, Ahn JB, Rha SY.
Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients *Cancer Chemother Pharmacol*. 2013 Oct Impact Factor 2.76 **Coauthor or Collaborator**
32. Kim KH, Yoon SH, Lee HJ, **Kim HS**, Shin SJ, Ahn JB, Rha SY.
Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma. *Cancer Chemother Pharmacol*. 2013 Oct; Impact Factor 2.76 **Coauthor or Collaborator**
33. Kim HS, Shin SJ, Kim SC, An S, Rha SY, Ahn JB, Cho BC, Choi HJ, Sohn JH, **Kim HS**, Chung HC, Kim JH, Roh JK, Lee S.
Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors. *Support Care Cancer*. 2013 Jun; Impact Factor 2.36 **Coauthor or Collaborator**
34. Kim HS, Kim HR, Kim GM, **Kim HS**, Koh YW, Kim SH, Choi EC, Hong YK, Sung JH, Kim SM, Kim JH, Cho BC.
The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma. *Cancer Chemother Pharmacol*. 2012 Oct Impact Factor 2.76 **Coauthor or Collaborator**
35. Lee HY, Shin SJ, **Kim HS**, Hong SJ, Han JW, Lim ST, Roh JK, Rha SY. Weekly gemcitabine and docetaxel in refractory soft tissue sarcoma: a retrospective analysis. *Cancer Res Treat*. 2012 Mar Impact Factor 0.25 **Coauthor or Collaborator**
36. Kim GM, Jeung HC, Rha SY, **Kim HS**, Jung I, Nam BH, Lee KH, Chung HC.
A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. *Eur J Cancer*. 2012 Mar Impact Factor 5.41 **Coauthor or Collaborator**
37. Chon HJ, Rha SY, Park HS, Shin SJ, **Kim HS**, Roh JK, Noh SH, Chung HC, Jeung HC
Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer. *Cancer Chemother Pharmacol*. 2011 Oct Impact Factor 2.76 **Coauthor or Collaborator**
38. Kim KH, Do IG, **Kim HS**, Chang MH, Kim HS, Jun HJ, Uhm J, Yi SY, Lim do H, Ji SH, Park MJ, Lee J, Park SH, Kwon GY, Lim HY.
Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy. *APMIS*. 2010 Dec Impact Factor 2.76 **Coauthor or Collaborator**
39. Yoon SH, Kim KH, Choi J, Kim GM, Kim JH, **Kim HS**, Park YN, Rha SY.
Novel sunitinib strategy in metastatic renal cell carcinoma on hemodialysis: intermittent dose of sunitinib after hemodialysis. *Cancer Res Treat*. 2010 Sep Impact Factor 0.25 **Coauthor or Collaborator**

40. Jung M, Shin HJ, Rha SY, Jeung HC, Hong S, Moon YW, **Kim HS**, Oh KJ, Yang WI, Roh JK, Chung HC.
The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with long-term follow-up. *Ann Surg Oncol*. 2010 Dec Impact Factor 3.93. **Coauthor or Collaborator**
41. Hong MH, **Kim HS**, Kim C, Ahn JR, Chon HJ, Shin SJ, Ahn JB, Chung HC, Rha SY.
Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. *Cancer Res Treat*. 2009 Jun Impact Factor 0.25 **Coauthor or Collaborator**
42. Park S, Holmes-Tisch AJ, Cho EY, Shim YM, Kim J, **Kim HS**, Lee J, Park YH, Ahn JS, Park K, Jänne PA, Ahn MJ.
Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. *J Thorac Oncol*. 2009 Jul Impact Factor 5.282 **Coauthor or Collaborator**
43. Ji SH, Lim do H, Yi SY, **Kim HS**, Jun HJ, Kim KH, Chang MH, Park MJ, Uhm JE, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK
A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer. *BMC Cancer*. 2009 Apr, Impact Factor 3.36, **Coauthor or Collaborator**
44. Chang MH, Kim KH, Jun HJ, **Kim HS**, Yi SY, Uhm JE, Park MJ, Lim do H, Ji SH, Hwang IG, Lee J, Park YH, Ahn JS, Ahn MJ, Park K.
Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer. *Cancer Chemother Pharmacol*. 2009 Oct; Impact Factor 2.76, **Coauthor or Collaborator**
45. Kim KH, Park YS, Chang MH, **Kim HS**, Jun HJ, Uhm J, Yi SY, Lim do H, Ji SH, Park MJ, Lee J, Park SH, Park JO, Lim HY, Kang WK.
A phase I/II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer, *Cancer Chemother Pharmacol*. 2009 Impact Factor 2.76, **Coauthor or Collaborator**
46. Yi SY, Park YS, **Kim HS**, Jun HJ, Kim KH, Chang MH, Park MJ, Uhm JE, Lee J, Park SH, Park JO, Lee JK, Lee KT, Lim HY, Kang WK.
Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer. *Cancer Chemother Pharmacol*. 2009 May Impact Factor 2.76, **Coauthor or Collaborator**
47. Lee J, Im YH, Cho EY, Hong YS, Lee HR, **Kim HS**, Kim MJ, Kim K, Kang WK, Park K, Shim YM.
A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. *Cancer Chemother Pharmacol*. 2008 Jun, Impact Factor 2.76, **Coauthor or Collaborator**

2. BOOK CHAPTERS

1. Sang Jin Chang (Editor). KyongHang Media. Patient Education Book for Colon Cancer.
Chapter 12. Management of chemotherapy toxicity for cancer patients. **Principal Author**.
2. Longo (Editor). MIP media. Principle of Internal Medicine (Korean Edition).
Chapter 24. Management of Bone and Soft Tissue Sarcoma. **Principal Author**.

E. Presentations and Special Lectures

- 2012 Feb **Invited Speaker**. Overview of solid tumors, Korean Cancer Study Group, KCSG
- 2014 April **Invited Speaker**. Overview of PI3K/PTEN/Akt signal pathway, The Korean Association of Internal

HYO SONG KIM

Medicine

- 2014 June **Invited Speaker.** Principle of systemic chemotherapy for soft tissue sarcoma, Annual Meeting of Korean Association for Clinical Oncology
- 2014 June **Invited Speaker.** Umbrella trial for advanced gastric cancer, Methodology Workshop, Korean Association for Clinical Oncology
- 2014 June **Invited Speaker.** Umbrella trial for advanced gastric cancer, Methodology Workshop, Korean Association for Clinical Oncology
- 2015 June **Invited Speaker.** Overview of sarcoma management, Novartis workshop
- 2016 Nov **Invited Speaker.** Practical challenges and solutions of sarcoma chemotherapy in Korea, Halaven Symposium, Eisai Korea Inc.